Induction chemoradiotherapy for advanced stage III non-small cell lung cancer: long-term follow-up in 42 patients

Katakami, Nobuyuki; Okazaki, Miki; Nishiuchi, S; Fukuda, Haruyuki; Horikawa, Tadao; Nishiyama, Hideki; Inui, Hiroshi; Bando, Kenshi

doi:10.1016/s0169-5002(98)00073-7

Cited by 18 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results compare favorably with those of previous trials of trimodality therapy in patients with locally advanced NSCLC, although comparing these results with those of other studies is difficult because of the inclusion of patients with different prognostic factors (8)(9)(10)(11)(12). In all of these studies, the response rates to induction chemoradiotherapy have ranged from 59 to 81%, the complete surgical resection rates have ranged from 45 to 81%, MSTs have ranged from 13 to 25 months, and survival rates at 2 years have ranged from 26 to 66% (8)(9)(10)(11)(12). Additionally, previous studies have reported that downstaging is correlated with rates of survival and distant recurrence (12,18).…”

Section: Discussionsupporting

confidence: 78%

“…Surgical mortality rates after induction chemoradiotherapy have ranged from 4 to 11% (8)(9)(10)(11)(12)20). In the present study, there were no treatment-related deaths.…”

Section: Discussionmentioning

confidence: 41%

“…Several combined treatment modalities have been used in an attempt to decrease the high rates of local recurrence and distant metastasis (17). Some phase II studies of induction chemoradiotherapy followed by surgery have obtained promising results for patients with locally advanced NSCLC (8)(9)(10)(11)(12). However, there is no evidence that induction chemoradiotherapy followed by surgery is superior to chemoradiotherapy or surgery alone.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, some phase II studies have examined induction chemoradiotherapy followed by surgery for patients with stage IIIA or IIIB NSCLC. These studies have shown promising results for patients with locally advanced NSCLC (8)(9)(10)(11)(12). However, the Intergroup 0139 trial has found that median progressionfree survival was significantly longer with chemoradiotherapy followed by surgery than with chemoradiotherapy alone for patients with pathologically proven N2 stage IIIA but that overall survival did not differ (13).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer

Kusumoto

Hirose²,

Fukayama³

et al. 2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. We examined the efficacy and toxicity of a divided schedule of cisplatin and vinorelbine with concurrent radiotherapy followed by surgery in patients with locally advanced non-small cell lung cancer (NSCLC). Patients with clinical stage IIIA or IIIB NSCLC were eligible if they had a performance status of 0 or 1, were 75 years or younger, and had adequate organ function. Patients were treated with cisplatin (40 mg/m 2 ) and vinorelbine (20 mg/m 2 ) on days 1 and 8 every 3 weeks. Thoracic radiotherapy (2 Gy per fraction; total dose, 40 Gy) was given concurrently. Surgical resection was performed after induction therapy had been completed. If disease was considered clinically inoperable after induction therapy, patients received 2 additional cycles of the chemotherapy and 20 Gy of additional radiotherapy. Twenty-three patients (20 men and 3 women; median age, 63 years; age range, 45-72 years) were enrolled. The overall response rate was 78.3%. Although grade 3-4 toxicities included neutropenia in 95.7% of patients and anemia in 39.1%, no grade 3-4 radiation pneumonitis or esophagitis occurred. Thirteen patients (56.5%) underwent thoracotomy and complete resection. There were no treatment-related deaths. The median survival time was 36 months (range, 4-78 months), the 2-year survival rate was 74%, and the median time to disease progression was 15 months (range, 2-59 months). This trimodality therapy is effective and well tolerated and is an acceptable therapeutic option for patients with locally advanced NSCLC.

show abstract

Section: Discussionsupporting

confidence: 78%

“…Surgical mortality rates after induction chemoradiotherapy have ranged from 4 to 11% (8)(9)(10)(11)(12)20). In the present study, there were no treatment-related deaths.…”

Section: Discussionmentioning

confidence: 41%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer

Kusumoto

Hirose²,

Fukayama³

et al. 2009

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Trimodality treatment for N2 NSCLC Most of the reports of the usefulness of the trimodality approach for N2 NSCLC are based on the results of phase II or retrospective trials of preoperative chemoradiotherapy (Faber et al, 1989;Rusch et al, 1993;Deutsch et al, 1994;Albain et al, 1995;Choi et al, 1997;Eberhardt et al, 1998;Katakami et al, 1998;Thomas et al, 1999;Doddoli et al, 2001;Martin et al, 2001;Stamatis et al, 2002;Sonett et al, 2004;Cerfolio et al, 2005;Daly et al, 2006). There are some highly promising and encouraging reports of long-term survival rates of around 30%, however, the toxicity is also substantial, usually exceeding that observed with other multimodality therapy.…”

Section: Specific Diseases Stage III N2 Diseasementioning

confidence: 99%

How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer

Kunitoh¹,

Suzuki²

2007

Br J Cancer

View full text Add to dashboard Cite

The trimodality approach represented by concurrent chemoradiotherapy followed by surgical resection is a highly effective, but potentially toxic therapy for locally advanced non-small-cell lung cancer (NSCLC). In this review, we discuss the current status of this therapy in patients with mediastinal node-positive (N2) stage III NSCLC or superior sulcus tumor, and present an overview of the principles for optimisation of the risk/benefit. Numerous clinical questions remain, and enrolment of patients into well-designed clinical trials should be encouraged.

show abstract

Hyperfractionated Irradiation with 3 Cycles of Induction Chemotherapy in Stage IIIA‐N2 Lung Cancer

et al. 2012

View full text Add to dashboard Cite

show abstract

Induction chemoradiotherapy for advanced stage III non-small cell lung cancer: long-term follow-up in 42 patients

Cited by 18 publications

References 31 publications

Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer

Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer

How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer

Hyperfractionated Irradiation with 3 Cycles of Induction Chemotherapy in Stage IIIA‐N2 Lung Cancer

Contact Info

Product

Resources

About